All News
TOFA and MTX: which one to withdraw first?
RCT in 100+ RA pts in remission after 1 yr, 1 yr follow-up
Withdraw MTX grp: Remission 30% LDA 40%
Withdraw TOFA grp: Remission 50% LDA 65%
diff NS small sample
8 SAEs, 72% recovery
https://t.co/tMnet32TWF
Abs#1586 #ACR22 @Rheumnow https://t.co/PWnkWYdlGk
Aurelie Najm AurelieRheumo ( View Tweet)
"Do patients care/look for telehealth in 2022?" Ben Nowell states patients have supported telehealth for access, convenience, and affordability (gas, parking, etc.) 60% of pts still like these visits. Are you doing telemed #ACR22? @RheumNow https://t.co/5fAHsp2kBD
Dr. Rachel Tate uptoTate ( View Tweet)
I see more and more studies on #ArtificialIntelligence using social media posts!
I think this is an extension/future of qualitative studies
40% of posts associated with negative sentiment toward #pregnancy #SLE fear and sadness!
#ACR22 abst#1335 @rheumnow https://t.co/qwk6pYeeXR
Bella Mehta bella_mehta ( View Tweet)
Cycling to 2nd after 1st line TNFi in AxSpA provides
◦ Limited benefits to pts
◦ Few pts showed clinically meaningful improvement in disease severity after 6 months
◦ Less than 25% pts remained on therapy after 2 years
Mease P Abs1499 https://t.co/0Txs82KRbx #ACR22 @RheumNow https://t.co/xJiIWe9yDp
Dr. Antoni Chan synovialjoints ( View Tweet)
Devauchelle-Pensec et al. SEMAPHORE RCT- tocilizumab in refractory PMR. TCZ treated GC dependent patients - better disease activity, reduced GC, less flare, more frequent GC-free remission @RheumNow #ACR22 Abstr#1106 https://t.co/UevgjF8di5 https://t.co/GmXqasNscp
Richard Conway RichardPAConway ( View Tweet)
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its Faculty
Dr. John Cush RheumNow ( View Tweet)
What to do next? Dazodalibep Rx in bDMARDs IR #RA pts. Dazo is a novel CD40 ligand antagonist Phase II RCT. N=78, multi dose phase II RCT. All doses improved DAS28. Dosing interval may be prolonged over time. Awaiting phase 3. Abst#2008 #ACR22 @RheumNow https://t.co/IrzflycKZp
Janet Pope Janetbirdope ( View Tweet)
#abst2132 #acr22 @rheumnow safety of Deucravacitinib Ph2PsA&ph3PSO trial: no Δ from BL in hematology, chemistry, or lipid labs. JAK 1/2/3 Effects on hem, hepatic, CPK, and cholesterol lab parameters not observed over 16 wks of DEUC at doses up to 12 mg QD & in combo w/csDMARDs. https://t.co/bjGEYp4GcJ
Olga Petryna DrPetryna ( View Tweet)
Hoffmann-Vold et al. SSc ILD frequently progresses even in long-standing SSc. Not just a disease of early SSc! @RheumNow #ACR22 Abstr#1536 https://t.co/nKiY2xFxfk https://t.co/W7SDm6QFpQ
Richard Conway RichardPAConway ( View Tweet)
Ghaffar et al. Chronic abdominal periaortitis. Imaging improved in only 57% and resolved in 9%. Incident aneurysms rare 8%. Older age and secondary cause assoc greater likelyhood improvement, smokers 2 times less likely. @RheumNow #ACR22 Abstr#1576 https://t.co/jS9djx3ZtU https://t.co/OFW2Jk7gGW
Richard Conway RichardPAConway ( View Tweet)
13S150. Draft ACR/EULAR APLS Classif Crit #ACR22
Entry: Clinical & +aPL w/in 3 yr
Then: Additive crit
-Don't count other cause
Clinical Domains: Macrovasc VTE, Macrovasc AT, Microvasc, Obst, Cardiac, Hematology
Lab: +LA, aCL/B2GP IgM/IgG/titer
Total: 3+ clin, 3+ lab
@RheumNow https://t.co/YeKW0orjZC
Eric Dein ericdeinmd ( View Tweet)
⬆️ serum anti-CCP3 Ab, absence IA
👉 StopRA trial - ironically stopped🛑
❌ hydroxychloroquine not superior to PBO in preventing/ delaying IA
👉rate of conversion to RA in CCP3+ve ~35% @ 3yrs
#ACR22 @RheumNow Abst#1604
Patricia Harkins DrTrishHarkins ( View Tweet)
“As long as you are practicing rheumatology, your legal risk is low.” - @greerdonley, law professor, on how rheumatologists should not let fear of legal consequences interfere w/practicing high quality evidenced based medicine for our patients #ReproductiveRheum #ACR22 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Makol @AshimaMakol et al. Multimorbidity in SSc . SSc higher burden multimorbidity at diagnosis and higher risk of developing multimorbidity over time @RheumNow #ACR22 Abstr#1190 https://t.co/VopFI6U5G5 https://t.co/hKKPC7v8EN
Richard Conway RichardPAConway ( View Tweet)
CorEVITAS Abs 1499 #ACRbest #ACR22 cycling to a second line TNFi provides limited benefits to pts with AxSpA who discontinued a first line TNFi. @RheumNow
https://t.co/fKDa5kPfXN https://t.co/CtMCj2Ihgc
Dr. Rachel Tate uptoTate ( View Tweet)
Mazareeb et al. von Willebrand Factor in systemic vasculitis. Increased in active vasculitis compared to remission and HCs. Correlates disease activity. Not affected by IL6i. @RheumNow #ACR22 Abstr#1573 https://t.co/uJAFHQpOlu https://t.co/PNX0puOeCn
Richard Conway RichardPAConway ( View Tweet)
Drop PJP prophylaxis in #SLE. Retrospec cohort 4900 SLE on MMF or CYP: 1 case of PJP detected over 2282 person years (incidence rate 0.44/1000 py); PJP prophylx cause neutropenia (IRR 4.7), leukopenia (IRR 4.0), C diff (IRR 3.9), hyperkalemia (IRR 3.7) abst#1594 ACR#22 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
#abs1601 #acr22 @rheumnow gender analysis of RCT 166 PsA pts on UST: F show ⬇️ response in resolution of pain, enthesitis, dactylitis& ACR response rates in both mono and MTXcombo groups. Unlike M, F seem not to benefit from UST+MTX combo for improvement of enthesitis& dactylitis https://t.co/a0uao6eWDO
Olga Petryna DrPetryna ( View Tweet)
Papagoras et al. Serum GM-CSF increased in AxSpA and persists despite TNFi. Are we going to have a trial of mavrilimumab in AxSpA then? @RheumNow #ACR22 Abstr#1156 https://t.co/wCFsY9nC1p https://t.co/lrQQ7tIX4x
Richard Conway RichardPAConway ( View Tweet)
BE COMPLETE study:
Bimekizumab (IL-17A and IL-17F inhibitor) efficacious in phase 3 trial for treatment of PsA. No new safety signals.
Abs#1599 @RheumNow #ACR22 https://t.co/iXj7wSRNeK
Robert B Chao, MD doctorRBC ( View Tweet)